Side-effects analysis gives Merck's new hep C med Zepatier an edge over older drugs

Merck & Co.'s ($MRK) hep C combo Zepatier has just hit the market, but the drug is already winning kudos for its side-effects profile. In a new analysis of clinical trial data, Zepatier turned up proportionally fewer serious side effects than Gilead Sciences' ($GILD) hep C combo treatment Harvoni and its veteran hep C med Sovaldi. Overall, Advera Health Analytics' report deemed Zepatier safer than Sovaldi and on par with Harvoni. More from FiercePharmaMarketing

Suggested Articles

A $300M pandemic ad campaign may be falling apart as HHS employees push back, celebrities balk and agency brass push a rushed timeline, Politico says.

Top communications execs at Johnson & Johnson and Pfizer joined a virtual discussion Tuesday to talk about pharma's reputation during the pandemic.

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.